Antibody-drug Conjugates-Europe Market Status and Trend Report 2013-2023
Report Summary
Antibody-drug Conjugates-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody-drug Conjugates industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Antibody-drug Conjugates 2013-2017, and development forecast 2018-2023
Main market players of Antibody-drug Conjugates in Europe, with company and product introduction, position in the Antibody-drug Conjugates market
Market status and development trend of Antibody-drug Conjugates by types and applications
Cost and profit status of Antibody-drug Conjugates, and marketing status
Market growth drivers and challenges
The report segments the Europe Antibody-drug Conjugates market as:
Europe Antibody-drug Conjugates Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Antibody-drug Conjugates Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Seattle Genetics technology
ImmunoGen technology
Immunomedics technology
Europe Antibody-drug Conjugates Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
IgG1 antibodies
HER2 antibodies
Europe Antibody-drug Conjugates Market: Players Segment Analysis (Company and Product introduction, Antibody-drug Conjugates Sales Volume, Revenue, Price and Gross Margin):
F. Hoffmann-La Roche
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Agensys
ALMAC Group
Ambrx
Astellas Pharma
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Antibody-drug Conjugates-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Antibody-drug Conjugates industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Antibody-drug Conjugates 2013-2017, and development forecast 2018-2023
Main market players of Antibody-drug Conjugates in Europe, with company and product introduction, position in the Antibody-drug Conjugates market
Market status and development trend of Antibody-drug Conjugates by types and applications
Cost and profit status of Antibody-drug Conjugates, and marketing status
Market growth drivers and challenges
The report segments the Europe Antibody-drug Conjugates market as:
Europe Antibody-drug Conjugates Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Antibody-drug Conjugates Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Seattle Genetics technology
ImmunoGen technology
Immunomedics technology
Europe Antibody-drug Conjugates Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
IgG1 antibodies
HER2 antibodies
Europe Antibody-drug Conjugates Market: Players Segment Analysis (Company and Product introduction, Antibody-drug Conjugates Sales Volume, Revenue, Price and Gross Margin):
F. Hoffmann-La Roche
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Agensys
ALMAC Group
Ambrx
Astellas Pharma
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTIBODY-DRUG CONJUGATES
1.1 Definition of Antibody-drug Conjugates in This Report
1.2 Commercial Types of Antibody-drug Conjugates
1.2.1 Seattle Genetics technology
1.2.2 ImmunoGen technology
1.2.3 Immunomedics technology
1.3 Downstream Application of Antibody-drug Conjugates
1.3.1 IgG1 antibodies
1.3.2 HER2 antibodies
1.4 Development History of Antibody-drug Conjugates
1.5 Market Status and Trend of Antibody-drug Conjugates 2013-2023
1.5.1 Europe Antibody-drug Conjugates Market Status and Trend 2013-2023
1.5.2 Regional Antibody-drug Conjugates Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Antibody-drug Conjugates in Europe 2013-2017
2.2 Consumption Market of Antibody-drug Conjugates in Europe by Regions
2.2.1 Consumption Volume of Antibody-drug Conjugates in Europe by Regions
2.2.2 Revenue of Antibody-drug Conjugates in Europe by Regions
2.3 Market Analysis of Antibody-drug Conjugates in Europe by Regions
2.3.1 Market Analysis of Antibody-drug Conjugates in Germany 2013-2017
2.3.2 Market Analysis of Antibody-drug Conjugates in United Kingdom 2013-2017
2.3.3 Market Analysis of Antibody-drug Conjugates in France 2013-2017
2.3.4 Market Analysis of Antibody-drug Conjugates in Italy 2013-2017
2.3.5 Market Analysis of Antibody-drug Conjugates in Spain 2013-2017
2.3.6 Market Analysis of Antibody-drug Conjugates in Benelux 2013-2017
2.3.7 Market Analysis of Antibody-drug Conjugates in Russia 2013-2017
2.4 Market Development Forecast of Antibody-drug Conjugates in Europe 2018-2023
2.4.1 Market Development Forecast of Antibody-drug Conjugates in Europe 2018-2023
2.4.2 Market Development Forecast of Antibody-drug Conjugates by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Antibody-drug Conjugates in Europe by Types
3.1.2 Revenue of Antibody-drug Conjugates in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Antibody-drug Conjugates in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Antibody-drug Conjugates in Europe by Downstream Industry
4.2 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Major Countries
4.2.1 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Germany
4.2.2 Demand Volume of Antibody-drug Conjugates by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Antibody-drug Conjugates by Downstream Industry in France
4.2.4 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Italy
4.2.5 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Spain
4.2.6 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Benelux
4.2.7 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Russia
4.3 Market Forecast of Antibody-drug Conjugates in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES
5.1 Europe Economy Situation and Trend Overview
5.2 Antibody-drug Conjugates Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTIBODY-DRUG CONJUGATES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Antibody-drug Conjugates in Europe by Major Players
6.2 Revenue of Antibody-drug Conjugates in Europe by Major Players
6.3 Basic Information of Antibody-drug Conjugates by Major Players
6.3.1 Headquarters Location and Established Time of Antibody-drug Conjugates Major Players
6.3.2 Employees and Revenue Level of Antibody-drug Conjugates Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTIBODY-DRUG CONJUGATES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 F. Hoffmann-La Roche
7.1.1 Company profile
7.1.2 Representative Antibody-drug Conjugates Product
7.1.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
7.2 Seattle Genetics
7.2.1 Company profile
7.2.2 Representative Antibody-drug Conjugates Product
7.2.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Seattle Genetics
7.3 Takeda Pharmaceuticals
7.3.1 Company profile
7.3.2 Representative Antibody-drug Conjugates Product
7.3.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
7.4 AbbVie
7.4.1 Company profile
7.4.2 Representative Antibody-drug Conjugates Product
7.4.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbbVie
7.5 AbGenomics
7.5.1 Company profile
7.5.2 Representative Antibody-drug Conjugates Product
7.5.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbGenomics
7.6 ADC Therapeutics
7.6.1 Company profile
7.6.2 Representative Antibody-drug Conjugates Product
7.6.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ADC Therapeutics
7.7 Agensys
7.7.1 Company profile
7.7.2 Representative Antibody-drug Conjugates Product
7.7.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Agensys
7.8 ALMAC Group
7.8.1 Company profile
7.8.2 Representative Antibody-drug Conjugates Product
7.8.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ALMAC Group
7.9 Ambrx
7.9.1 Company profile
7.9.2 Representative Antibody-drug Conjugates Product
7.9.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Ambrx
7.10 Astellas Pharma
7.10.1 Company profile
7.10.2 Representative Antibody-drug Conjugates Product
7.10.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Astellas Pharma
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY-DRUG CONJUGATES
8.1 Industry Chain of Antibody-drug Conjugates
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY-DRUG CONJUGATES
9.1 Cost Structure Analysis of Antibody-drug Conjugates
9.2 Raw Materials Cost Analysis of Antibody-drug Conjugates
9.3 Labor Cost Analysis of Antibody-drug Conjugates
9.4 Manufacturing Expenses Analysis of Antibody-drug Conjugates
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY-DRUG CONJUGATES
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Antibody-drug Conjugates in This Report
1.2 Commercial Types of Antibody-drug Conjugates
1.2.1 Seattle Genetics technology
1.2.2 ImmunoGen technology
1.2.3 Immunomedics technology
1.3 Downstream Application of Antibody-drug Conjugates
1.3.1 IgG1 antibodies
1.3.2 HER2 antibodies
1.4 Development History of Antibody-drug Conjugates
1.5 Market Status and Trend of Antibody-drug Conjugates 2013-2023
1.5.1 Europe Antibody-drug Conjugates Market Status and Trend 2013-2023
1.5.2 Regional Antibody-drug Conjugates Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Antibody-drug Conjugates in Europe 2013-2017
2.2 Consumption Market of Antibody-drug Conjugates in Europe by Regions
2.2.1 Consumption Volume of Antibody-drug Conjugates in Europe by Regions
2.2.2 Revenue of Antibody-drug Conjugates in Europe by Regions
2.3 Market Analysis of Antibody-drug Conjugates in Europe by Regions
2.3.1 Market Analysis of Antibody-drug Conjugates in Germany 2013-2017
2.3.2 Market Analysis of Antibody-drug Conjugates in United Kingdom 2013-2017
2.3.3 Market Analysis of Antibody-drug Conjugates in France 2013-2017
2.3.4 Market Analysis of Antibody-drug Conjugates in Italy 2013-2017
2.3.5 Market Analysis of Antibody-drug Conjugates in Spain 2013-2017
2.3.6 Market Analysis of Antibody-drug Conjugates in Benelux 2013-2017
2.3.7 Market Analysis of Antibody-drug Conjugates in Russia 2013-2017
2.4 Market Development Forecast of Antibody-drug Conjugates in Europe 2018-2023
2.4.1 Market Development Forecast of Antibody-drug Conjugates in Europe 2018-2023
2.4.2 Market Development Forecast of Antibody-drug Conjugates by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Antibody-drug Conjugates in Europe by Types
3.1.2 Revenue of Antibody-drug Conjugates in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Antibody-drug Conjugates in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Antibody-drug Conjugates in Europe by Downstream Industry
4.2 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Major Countries
4.2.1 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Germany
4.2.2 Demand Volume of Antibody-drug Conjugates by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Antibody-drug Conjugates by Downstream Industry in France
4.2.4 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Italy
4.2.5 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Spain
4.2.6 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Benelux
4.2.7 Demand Volume of Antibody-drug Conjugates by Downstream Industry in Russia
4.3 Market Forecast of Antibody-drug Conjugates in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES
5.1 Europe Economy Situation and Trend Overview
5.2 Antibody-drug Conjugates Downstream Industry Situation and Trend Overview
CHAPTER 6 ANTIBODY-DRUG CONJUGATES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Antibody-drug Conjugates in Europe by Major Players
6.2 Revenue of Antibody-drug Conjugates in Europe by Major Players
6.3 Basic Information of Antibody-drug Conjugates by Major Players
6.3.1 Headquarters Location and Established Time of Antibody-drug Conjugates Major Players
6.3.2 Employees and Revenue Level of Antibody-drug Conjugates Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ANTIBODY-DRUG CONJUGATES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 F. Hoffmann-La Roche
7.1.1 Company profile
7.1.2 Representative Antibody-drug Conjugates Product
7.1.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
7.2 Seattle Genetics
7.2.1 Company profile
7.2.2 Representative Antibody-drug Conjugates Product
7.2.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Seattle Genetics
7.3 Takeda Pharmaceuticals
7.3.1 Company profile
7.3.2 Representative Antibody-drug Conjugates Product
7.3.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
7.4 AbbVie
7.4.1 Company profile
7.4.2 Representative Antibody-drug Conjugates Product
7.4.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbbVie
7.5 AbGenomics
7.5.1 Company profile
7.5.2 Representative Antibody-drug Conjugates Product
7.5.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbGenomics
7.6 ADC Therapeutics
7.6.1 Company profile
7.6.2 Representative Antibody-drug Conjugates Product
7.6.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ADC Therapeutics
7.7 Agensys
7.7.1 Company profile
7.7.2 Representative Antibody-drug Conjugates Product
7.7.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Agensys
7.8 ALMAC Group
7.8.1 Company profile
7.8.2 Representative Antibody-drug Conjugates Product
7.8.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ALMAC Group
7.9 Ambrx
7.9.1 Company profile
7.9.2 Representative Antibody-drug Conjugates Product
7.9.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Ambrx
7.10 Astellas Pharma
7.10.1 Company profile
7.10.2 Representative Antibody-drug Conjugates Product
7.10.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Astellas Pharma
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY-DRUG CONJUGATES
8.1 Industry Chain of Antibody-drug Conjugates
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY-DRUG CONJUGATES
9.1 Cost Structure Analysis of Antibody-drug Conjugates
9.2 Raw Materials Cost Analysis of Antibody-drug Conjugates
9.3 Labor Cost Analysis of Antibody-drug Conjugates
9.4 Manufacturing Expenses Analysis of Antibody-drug Conjugates
CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTIBODY-DRUG CONJUGATES
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
